Skyrizi (risankizumab)

pCPA File Number: 21123
Negotiation Status:
Concluded with an LOI
Indication(s):
Psoriasis, moderate to severe plaque
Sponsor/Manufacturer:
AbbVie Corporation
CDA-AMC Project Number:
SR0583-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: